233 related articles for article (PubMed ID: 23063354)
1. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Al-Batran SE; Pauligk C; Homann N; Hartmann JT; Moehler M; Probst S; Rethwisch V; Stoehlmacher-Williams J; Prasnikar N; Hollerbach S; Bokemeyer C; Mahlberg R; Hofheinz RD; Luley K; Kullmann F; Jäger E
Eur J Cancer; 2013 Mar; 49(4):835-42. PubMed ID: 23063354
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
[TBL] [Abstract][Full Text] [Related]
4. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Kripp M; Al-Batran SE; Rosowski J; Pauligk C; Homann N; Hartmann JT; Moehler M; Hofheinz RD
Gastric Cancer; 2014 Jan; 17(1):181-7. PubMed ID: 23455717
[TBL] [Abstract][Full Text] [Related]
5. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
7. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Homann N; Pauligk C; Luley K; Werner Kraus T; Bruch HP; Atmaca A; Noack F; Altmannsberger HM; Jäger E; Al-Batran SE
Int J Cancer; 2012 Apr; 130(7):1706-13. PubMed ID: 21618509
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford HE; Marshall A; Bridgewater JA; Janowitz T; Coxon FY; Wadsley J; Mansoor W; Fyfe D; Madhusudan S; Middleton GW; Swinson D; Falk S; Chau I; Cunningham D; Kareclas P; Cook N; Blazeby JM; Dunn JA;
Lancet Oncol; 2014 Jan; 15(1):78-86. PubMed ID: 24332238
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.
Hejna M; Raderer M; Zacherl J; Ba-Ssalamah A; Püspök A; Schmidinger M; Pluschnig U; Brodowicz T; Zielinski CC
Anticancer Drugs; 2008 Jun; 19(5):535-9. PubMed ID: 18418220
[TBL] [Abstract][Full Text] [Related]
12. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Kaechele V; Moehler M; Lutz MP; von Wichert G; Eisele M; Klaus J; Galle PR; Adler G; Seufferlein T
Cancer Chemother Pharmacol; 2010 May; 66(1):191-5. PubMed ID: 20354701
[TBL] [Abstract][Full Text] [Related]
14. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
18. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
Rosati G; Cordio S; Tucci A; Blanco G; Bordonaro R; Reggiardo G; Manzione L
Oncology; 2005; 69(2):122-9. PubMed ID: 16118508
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Osaka Y; Shinohara M; Hoshino S; Ogata T; Takagi Y; Tsuchida A; Aoki T
Anticancer Res; 2011 Feb; 31(2):633-8. PubMed ID: 21378349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
